ABSTRACT
Identifying immune processes required for liver-stage sterilizing immunity to malaria infection remains an open problem. The IMRAS trial comprised 5x immunizations with radiation-attenuated sporozoites resulting in 55% protection from subsequent challenge. To identify correlates of vaccination and protection, we performed detailed systems immunology longitudinal profiling of the entire trial time course including whole blood transcriptomics, detailed PBMC cell phenotyping and serum antigen array profiling of 11 IMRAS RAS vaccinees at up to 21 timepoints each. RAS vaccination induced serum antibody responses to CSP, TRAP, and AMA1 in all vaccinees. We observed large numbers of differentially expressed genes associated with vaccination response and protection, with distinctly differing transcriptome responses elicited after each immunization. These included inflammatory and proliferative responses, as well as increased abundance of monocyte and DC subsets after each immunization. Increases Vδ2 γδ T cells and MAIT cells were observed in response to immunization over the course of study. Interferon responses strongly differed between protected and non-protected individuals with high interferon responses after the 1stimmunization, but not the 2nd-5th. Blood transcriptional interferon responses were correlated with abundances of different circulating classical and non-classical monocyte populations.
This study has revealed multiple coordinated immunological processes induced by vaccination and associated with protection. Our work represents the most detailed immunological profiling of a RAS vaccine trial performed to date and will guide the design and interpretation of future malaria vaccine trials.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT01994525
Funding Statement
This work was supported by National Institutes of Health (https://www.nih.gov/grants-funding) grant U19AI128914 (to K.D.S and M.J.M), Bill & Melinda Gates Foundation (https://www.ghvap.org/Pages/default.aspx) grant GHVAP NG-ID18-Stuart (to K.D.S) and National Institute of General Medical Sciences (https://www.nigms.nih.gov/) grant P41GM109824 to (J.D.A). The IMRAS clinical trial was funded by the Bill & Melinda Gates Foundation (BMGF) through Global Health Grant Number OPP1034596 awarded to the Naval Medical Research Center (NMRC) under cooperative research and development agreement (CRADA) NMRC-12-3941 and NMRC-15-0579. The funders had no role in study design, data collection, analysis and in decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted at the Naval Medical Research Center (NMRC) Clinical Trials Center from 2014 to 2016; controlled human malaria infections (CHMIs) were conducted at the Walter Reed Army Institute of Research (WRAIR) secure insectary. The study protocol was reviewed and approved by the NMRC Institutional Review Board in compliance with all federal regulations governing the protection of human subjects. WRAIR holds a Federal-wide Assurance from the Office of Human Research Protections (OHRP) under the Department of Health and Human Services as does NMRC. NMRC also holds a Department of Defense/Department of the Navy Federal- wide Assurance for human subject protections.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Whole blood transcriptional data is available on NCBI GEO under accessions GSE116619 (Days 0-28) and GSE192756 (Days 31-140). Antibody microarray profiling results and flow cytometry subset counts are available as Datafiles S 4 and S 5 respectively, with raw data available in ImmPort.
